Your browser doesn't support javascript.
loading
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.
Verstovsek, Srdan; Vannucchi, Alessandro M; Griesshammer, Martin; Masszi, Tamas; Durrant, Simon; Passamonti, Francesco; Harrison, Claire N; Pane, Fabrizio; Zachee, Pierre; Kirito, Keita; Besses, Carlos; Hino, Masayuki; Moiraghi, Beatriz; Miller, Carole B; Cazzola, Mario; Rosti, Vittorio; Blau, Igor; Mesa, Ruben; Jones, Mark M; Zhen, Huiling; Li, Jingjin; Francillard, Nathalie; Habr, Dany; Kiladjian, Jean-Jacques.
Afiliación
  • Verstovsek S; The University of Texas MD Anderson Cancer Center, Houston, TX, USA sverstov@mdanderson.org.
  • Vannucchi AM; Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Italy.
  • Griesshammer M; Johannes Wesling Clinic, Minden, Germany.
  • Masszi T; St. István and St. László Hospital, Semmelweis University 3 Department of Internal Medicine, Budapest, Hungary.
  • Durrant S; Royal Brisbane & Women's Hospital, Brisbane, QLD, Australia.
  • Passamonti F; Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy.
  • Harrison CN; Guy's and St. Thomas' NHS Foundation Trust, London, UK.
  • Pane F; University of Naples Federico II, Italy.
  • Zachee P; ZNA Stuivenberg, Antwerp, Belgium.
  • Kirito K; Department of Hematology and Oncology, University of Yamanshi, Chuo-shi, Japan.
  • Besses C; Hematology Department, Hospital del Mar, Barcelona, Spain.
  • Hino M; Department of Clinical Hematology and Diagnostics, Osaka City University Graduate School of Medicine, Japan.
  • Moiraghi B; Hospital Jose Maria Ramos Mejia, Buenos Aires, Argentina.
  • Miller CB; Saint Agnes Cancer Institute, Baltimore, MD, USA.
  • Cazzola M; Department of Hematology, University of Pavia, Italy.
  • Rosti V; Center for the Study of Myelofibrosis, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
  • Blau I; Medical Department, Division of Hematology, Oncology, and Tumor Immunology, Charité Universitätsmedizin Berlin, Germany.
  • Mesa R; Department of Hematology/Oncology, Mayo Clinic Cancer Center, Scottsdale, AZ, USA.
  • Jones MM; Incyte Corporation, Wilmington, DE, USA.
  • Zhen H; Incyte Corporation, Wilmington, DE, USA.
  • Li J; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Francillard N; Novartis Pharma S.A.S, Rueil Malmaison, France.
  • Habr D; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Kiladjian JJ; Centre d'Investigations Cliniques (INSERM CIC 1427), Hôpital Saint-Louis and Université Paris Diderot, Paris, France.
Haematologica ; 101(7): 821-9, 2016 07.
Article en En | MEDLINE | ID: mdl-27102499
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Policitemia Vera / Pirazoles / Inhibidores de Proteínas Quinasas Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Haematologica Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Policitemia Vera / Pirazoles / Inhibidores de Proteínas Quinasas Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Haematologica Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos